InMed Pharmaceuticals (INM) Net Cash Flow Growth (3y) (2022 - 2026)
InMed Pharmaceuticals (INM) Net Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.36 Mn | 1.11 Mn | - | 7.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.49% |
| Dec 31, 2025 | -42.82% |
| Sep 30, 2025 | -36.62% |
| Jun 30, 2025 | 184.23% |
| Mar 31, 2025 | 30.73% |
| Dec 31, 2024 | 18.95% |
| Sep 30, 2024 | -28.54% |
| Jun 30, 2024 | 21.03% |
| Mar 31, 2024 | -50.56% |
| Dec 31, 2023 | -33.11% |
| Sep 30, 2023 | -14.82% |
| Jun 30, 2023 | 20.91% |
| Mar 31, 2023 | -6.51% |
| Dec 31, 2022 | 48.56% |
| Sep 30, 2022 | 32.04% |